Lyudmila Bazhenova, MD, FASCO, outlines key considerations for treatment intensification in EGFR-mutated NSCLC.
Commentary|Videos|November 6, 2024
Adopting Broader Clinical Trial Eligibility in Lung Cancer With Brain Mets, Leptomeningeal Disease
Author(s)Ivy Riano, MD
Ivy Riano, MD, of Dartmouth Geisel School of Medicine, discusses the adoption of broader clinical trial eligibility in lung cancer, specifically for those with brain metastases or leptomeningeal disease.
Advertisement
Ivy Riano, MD, of Dartmouth Geisel School of Medicine, discusses the adoption of broader clinical trial eligibility in lung cancer, specifically for those with brain metastases or leptomeningeal disease.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Dr Lee on the Optimal Duration of Adjuvant Osimertinib in EGFR+ NSCLC
5